HR and breast carcinoma: In this study, we conducted a comprehensive analysis of lncRNA expression profiles in 96 well-characterized breast cancer samples, categorized into distinct molecular subtypes, including Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Positive (HER2 + ), HER2 + HR+ dual-positive, and TNBC.